Qian Nie

Dr. Qian Nie


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2026 in Cancers
Verified
Journal Article
Open access
PDF file
SKSakshi Khurana
Sakshi Khurana
VKViriya Keo
Viriya Keo
ALAlexandra Larson
Alexandra Larson
VUVindhya Udhane
Vindhya Udhane
JAJennifer N Adams
Jennifer N Adams
Honey V Reddi, PhD, FACMGHoney V Reddi, PhD, FACMG
Honey V Reddi, PhD, FACMG
Background/Objectives: The latest National Comprehensive Cancer Network (NCCN) Central Nervous System (CNS) Guidelines recommend utilizing next-generation sequencing (NGS) to enable comprehensive genomic profiling (CGP) as the preferred approach for molecular characterization of central nervous system (CNS) malignancies. CNS malignancies present distinct challenges due to the infeasibility of tissue-based testing for many patients and the restrictive nature of the blood–brain barrier (BBB) making plasma-based liquid biopsy an ineffective alternative. Recent advances in liquid biopsy have extended molecular testing beyond plasma to include cerebrospinal fluid (CSF), which serves as a valuable source for tumor-derived nucleic acids. Methods: The Belay Summit™ 2.0 is a high-throughput CGP assay capable of detecting multiple variant types, including single nucleotide variants (SNVs) and small insertion and deletions (Indels), copy number variations (CNVs), gene fusions, splice variants, and immunotherapy biomarkers such as microsatellite instability (MSI) and tumor mutational burden (TMB). This study details the analytical and clinical validation of Summit™ 2.0 to assess its technical performance and clinical sensitivity. Analytical validation was conducted using 68 specimens, demonstrating robust and reproducible detection of all variant types with 15 ng of CSF-derived total nucleic acid (tNA). Results: The analytical sensitivity of the Belay Summit™ 2.0 assay for SNVs and Indels was determined to be 96.7% with a 100% limit of detection (LoD) at a variant allele frequency of 0.3%. Clinical validity was evaluated across a cohort of 118 CSF specimens, including both primary and metastatic CNS tumors, demonstrating 96% sensitivity and 98% specificity. Conclusions: These findings support the use of the Belay Summit™ 2.0 assay for accurate and reproducible genomic profiling of CNS tumors using tumor-derived nucleic acids from CSF in patients for whom tissue-based testing is considered infeasible, unsafe, or not deemed by the prescribing physician to be clinically appropriate.

11 October 2025 in Diseases
Verified
Journal Article
Open access
PDF file
MYMichael Youssef
Michael Youssef
ALAlexandra Larson
Alexandra Larson
VUVindhya Udhane
Vindhya Udhane
VKViriya Keo
Viriya Keo
KSKala Frances Schilter
Kala Frances Schilter
Honey V Reddi, PhD, FACMGHoney V Reddi, PhD, FACMG
Honey V Reddi, PhD, FACMG
A woman in her 40s with a history of ER/PR+, HER2-negative breast cancer presented with a seizure three years after mastectomy. Magnetic resonance imaging (MRI) revealed a right caudate head mass, which was concerning for either high-grade glioma or metastatic disease, but biopsy was deemed too high risk. Cerebrospinal fluid (CSF) tumor-derived DNA (tDNA) analysis by next-generation sequencing (NGS) was ordered, revealing a gain-of-function variant in PIK3CA, ERBB2 copy number gain, and high aneuploidy, findings consistent with breast cancer brain metastasis. Based on these results, the patient was treated with stereotactic radiosurgery (SRS) followed by trastuzumab deruxtecan, a HER2-targeted therapy. This case highlights the diagnostic and therapeutic value of CSF tDNA analysis in central nervous system (CNS) lesions when biopsy is not feasible. The report also illustrates how clonal evolution, such as acquired ERBB2 amplification, can occur in metastatic disease and influence treatment decisions.

17 April 2026 in Cancers
Verified
Journal Article
Open access
PDF file
QNQian Nie
Qian Nie
KSKala Frances Schilter
Kala Frances Schilter
ALAlexandra Larson
Alexandra Larson
VUVindhya Udhane
Vindhya Udhane
VKViriya Keo
Viriya Keo
Honey V Reddi, PhD, FACMGHoney V Reddi, PhD, FACMG
Honey V Reddi, PhD, FACMG
Background: Evaluation of chromosome aneuploidy and gene-level copy number alterations for diagnosis, prognosis, and therapeutic decision-making in solid tumors is the standard of care. Chromosomal microarray (CMA), next-generation sequencing (NGS), immunohistochemistry (IHC), and fluorescence in situ hybridization (FISH) are the gold standard for detecting these variants in tumor tissue. In contrast to most solid tumors, cancers of the central nervous system (CNS) pose a unique challenge for effective detection via plasma due to the blood–brain barrier (BBB), with the additional challenges of brain biopsy or surgery being highly invasive and posing a significant risk to the patient. The Belay Ascent™ liquid biopsy test uses low-pass whole-genome sequencing (LP-WGS) to report on chromosome arm-level aneuploidy and gene-level copy number variants (CNVs) in cerebrospinal fluid (CSF) to inform diagnosis, prognosis, and therapeutic decision-making in CNS tumors. Methods: This study presents the equivalence of Ascent™ in detecting chromosome arm-level aneuploidy and gene-level CNVs using 48 tissue specimens followed by a clinical validation using a cohort of 32 CSF specimens with matched tissue-based tumor profiling information. Results: Equivalence of Ascent™ in detecting chromosome arm-level aneuploidy and gene-level CNVs using 48 tissue specimens was shown to have 100% and 97% positive percent agreement (PPA), respectively, compared to the gold standard of CMA/NGS. The validation cohort of 32 CSF specimens demonstrated 78% and 90% PPA for aneuploidy and gene-level CNVs, respectively. Clinical impact of Ascent™ was demonstrated, with 243 production cases able to inform the diagnosis and management of CNS tumors with high accuracy. Conclusions: Given the paucity of cells in CSF, limiting the use of karyotyping, CMA, IHC, and FISH, the Belay Ascent™ test provides a highly sensitive novel minimally invasive method for the evaluation of chromosome aneuploidy and gene-level CNVs in CSF.

27 March 2026 in Cancers
Verified
Journal Article
Open access
PDF file
MYMichael Youssef
Michael Youssef
ALAlexandra Larson
Alexandra Larson
VUVindhya Udhane
Vindhya Udhane
ZJZhixin Jiang
Zhixin Jiang
DLDaniel Lim
Daniel Lim
Honey V Reddi, PhD, FACMGHoney V Reddi, PhD, FACMG
Honey V Reddi, PhD, FACMG
Background: Cytology from cerebrospinal fluid (CSF) is standard-of-care to detect central nervous system (CNS) cancers but suffers from low-sensitivity and lacks associated molecular information, often requiring brain biopsy or resection to obtain. Belay Diagnostics offers analytically and clinically validated CSF-based tests to support the diagnosis and management of primary and secondary CNS cancers. However, the clinical utility (CU) of these assays has not been previously evaluated. Methods: This retrospective study presents a real-world, single institution experience of using the Belay Summit liquid biopsy test for all orders received (n = 123) between October 2024 and September 2025. Clinical information was reviewed for demographics, provisional diagnosis, oncology history, CSF cytology results, and tumor genomic profiling results. The primary endpoint of this study was to evaluate the impact of Belay CSF-based assays on physician diagnosis and treatment decisions. Secondary endpoints included evaluating the clinical performance of the Belay Summit test verses cytology in CNS malignancy detection (sensitivity, specificity, and accuracy). Results: The cohort included 120 patients with suspected or previously diagnosed primary (n = 40) or metastatic (n = 80) CNS tumors; three patients completed longitudinal testing for a total of 123 specimens and test orders. Summit showed higher sensitivity for CNS malignancy (90%) over CSF cytology (12%). The Belay CSF liquid biopsy test demonstrated strong clinical utility and was essential to clinical course pursued in 93% (114/123) of specimens, informing treatment and management decisions. Conclusions: The Belay Summit test provides clinically meaningful information to support physician decision-making for the diagnosis and management of primary and secondary CNS tumors, especially in cases where tissue sampling is infeasible.

13 March 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
VUVindhya Udhane
Vindhya Udhane
ALAlexandra Larson
Alexandra Larson
JAJennifer N Adams
Jennifer N Adams
RJRakshitha Jagadish
Rakshitha Jagadish
AAAnthony Acevedo
Anthony Acevedo
Honey V Reddi, PhD, FACMGHoney V Reddi, PhD, FACMG
Honey V Reddi, PhD, FACMG
Background: Diagnosis of leptomeningeal disease (LMD) remains a clinical challenge due to nonspecific neurological symptoms, limitations of imaging, and the low sensitivity of cerebrospinal fluid (CSF) cytology. Molecular biomarkers, such as circulating tumor DNA (ctDNA) variant allele frequencies (VAFs), offer potential for improved detection and disease monitoring. Methods: Gene-level VAFs were analyzed from 118 Summit™ positive CSF specimens and evaluated in the context of clinical diagnosis, neurological presentation, neuroimaging, and CSF cytology. Longitudinal analyses were performed on serial CSF samples to assess VAF dynamics following therapy. Results: Longitudinal assessment demonstrated that decreases in VAF post-treatment aligned with clinical stabilization, whereas rising or persistent VAFs reflected disease progression, therapeutic resistance, or evolving clonal mutations. Elevated VAFs correlated strongly with clinically confirmed LMD and were concordant with radiographic and clinical indicators of disease. Conclusions: VAF analysis in CSF provides a quantitative biomarker for the detection and monitoring of metastatic CNS disease. These findings support its utility as a complementary tool to conventional diagnostics, offering real-time insights into disease burden, therapeutic response, and clonal evolution in LMD.

Verified
Journal Article
Open access
PDF file
VKViriya Keo
Viriya Keo
SKSakshi Khurana
Sakshi Khurana
VUVindhya Udhane
Vindhya Udhane
ALAlexandra Larson
Alexandra Larson
JAJennifer N Adams
Jennifer N Adams
Honey V Reddi, PhD, FACMGHoney V Reddi, PhD, FACMG
Honey V Reddi, PhD, FACMG
Background: Evaluation of gene-level copy number variants (CNVs) for diagnosis and therapeutic decision making has become standard of care with next-generation sequencing (NGS), immunohistochemistry (IHC), and/or fluorescence in situ hybridization (FISH) being used to detect gene amplifications/deletions in tumor tissue. In contrast to most solid tumors, CNS cancers are challenging to evaluate by resection and/or biopsy due to the associated risks with invasive brain surgery that can also result in death or associated morbidity and therefore alternate methods are required.Methods: This study presents the analytical validation of using quantitative PCR (qPCR) to detect gene CNVs directly from cerebrospinal fluid (CSF)-derived DNA and from the AscentTM low-pass whole genome sequencing (LP-WGS) libraries, demonstrating concordance with the gold standard of NGS/IHC/FISH used in tumor tissue. Results: The analytical sensitivity of qPCR to detect gene amplification calls for ERBB2 (erb-b2 receptor tyrosine kinase 2) was demonstrated to be 100% and that of EGFR (epidermal growth factor receptor) was 83%, with specificities of 96% and 100%, respectively. The analytical sensitivity of qPCR to detect gene deletions for CDKN2A/2B (cyclin-dependent kinase inhibitor 2A/2B) was 60% and that for MTAP (methylthioadenosine phosphorylase) was 100% with a specificity of 100% for all three genes. AscentTM was demonstrated to have a higher sensitivity (100%) when compared to qPCR for the same genes evaluated and demonstrated 100% positive agreement and 100% negative agreement with known CNV status. Conclusions: The results demonstrate that given the paucity of cells in CSF limiting the use of IHC and FISH, qPCR and AscentTM provide highly sensitive, novel, minimally invasive methods for the evaluation of gene copy number (CN) status to inform the diagnosis and management of CNS cancers.